{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:32:36Z","timestamp":1790623956830,"version":"4.1.0"},"reference-count":87,"publisher":"Informa UK Limited","issue":"28","license":[{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Food and Drug Administration"},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2019,10,31]]},"DOI":"10.2217\/fon-2019-0368","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T08:40:01Z","timestamp":1565340001000},"page":"3267-3281","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":67,"title":["Humanistic and Economic Impact of Subcutaneous Versus Intravenous Administration of Oncology Biologics"],"prefix":"10.1080","volume":"15","author":[{"given":"Kenneth C","family":"Anderson","sequence":"first","affiliation":[{"name":"Division of Hematologic Neoplasia, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C","family":"Arend","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Comprehensive Cancer Center, Experimental Therapeutics Program, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Chou","sequence":"additional","affiliation":[{"name":"Pfizer, San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira A","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Pfizer, New York, NY 10017, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,8,9]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10030083"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0295-0"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.08.001"},{"key":"e_1_3_4_6_1","unstructured":"Prescribing Information . Rituxan Hycela (rituxan and hyaluronidase human) injection for subcutaneous use(2017). https:\/\/www.gene.com\/download\/pdf\/rituxan_hycela_prescribing.pdf"},{"key":"e_1_3_4_7_1","unstructured":"Prescribing Information . Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) injection for subcutaneous use (2019). https:\/\/www.gene.com\/download\/pdf\/herceptin_hylecta_prescribing.pdf"},{"key":"e_1_3_4_8_1","unstructured":"Prescribing Information . Velcade (bortezomib) for injection for cutaneous or intravenous use (2017). http:\/\/www.velcade.com\/Files\/PDFs\/Velcade_Prescribing_Information.pdf"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0836"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e15138"},{"issue":"8","key":"e_1_3_4_11_1","first-page":"1140PD","article-title":"Phase I study of KN035, a novel fusion anti-PD-L1 antibody administered subcutaneously in patients with advanced solid tumors in the USA","volume":"29","author":"Papadopoulos KP","year":"2018","unstructured":"Papadopoulos KP , HarbW, LuNet al. Phase I study of KN035, a novel fusion anti-PD-L1 antibody administered subcutaneously in patients with advanced solid tumors in the USA. Ann. Oncol.29(Suppl. 8), 1140PD (2018).","journal-title":"Ann. Oncol."},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1362"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e14089"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.838.838"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647"},{"issue":"3","key":"e_1_3_4_16_1","first-page":"167","article-title":"Safety and efficacy of SC versus IV bortezomib in patients with newly elderly diagnosed multiple myeloma","volume":"102","author":"Bacchiarri F","year":"2017","unstructured":"Bacchiarri F , NozzoliC, AntonioliEet al. Safety and efficacy of SC versus IV bortezomib in patients with newly elderly diagnosed multiple myeloma. Haematologica102(Suppl. 3), 167 (2017).","journal-title":"Haematologica"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013503122"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.4236\/abcr.2013.24022"},{"key":"e_1_3_4_19_1","first-page":"A130","article-title":"Budget impact analysis of the use of trastuzumab SC in the treatment of HER2 positive in public health institutions of Ecuador","volume":"20","author":"Calvache J","year":"2017","unstructured":"Calvache J , BricenoV. Budget impact analysis of the use of trastuzumab SC in the treatment of HER2 positive in public health institutions of Ecuador. Value Health20, A130 (2017).","journal-title":"Value Health"},{"issue":"4","key":"e_1_3_4_20_1","article-title":"Do patients and nurses outside clinical trial prefer SC trastuzumab over conventional IV infusion? Instituto Oncologico Nacional experience","volume":"77","author":"Castillo-Fernandez O","year":"2017","unstructured":"Castillo-Fernandez O , CabrejaA, ArauzEet al. Do patients and nurses outside clinical trial prefer SC trastuzumab over conventional IV infusion? Instituto Oncologico Nacional experience. Cancer Res.77(Suppl. 4), P5-11-16 (2017).","journal-title":"Cancer Res."},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.07.135"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.07.123"},{"issue":"4","key":"e_1_3_4_23_1","article-title":"BELIS: safety and tolerability of at home administration of trastuzumab (Herceptin) SC for the treatment of patients with HER2-positive early breast cancer","volume":"77","author":"Cocquyt VF","year":"2017","unstructured":"Cocquyt VF , Martinez-MenaCL, MartensMTet al. BELIS: safety and tolerability of at home administration of trastuzumab (Herceptin) SC for the treatment of patients with HER2-positive early breast cancer. Cancer Res.77(4; Suppl. 1), P4-21-17 (2017).","journal-title":"Cancer Res."},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30078-9"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70005-1"},{"issue":"6","key":"e_1_3_4_26_1","doi-asserted-by":"crossref","first-page":"e0157957","DOI":"10.1371\/journal.pone.0157957","article-title":"Time savings with rituximab SC injection versus rituximab IV infusion: a time and motion study in eight countries","volume":"11","author":"De Cock E","year":"2016","unstructured":"De Cock E , KritikouP, SandovalMet al. Time savings with rituximab SC injection versus rituximab IV infusion: a time and motion study in eight countries. PLoS ONE11(6), e0157957 (2016).","journal-title":"PLoS ONE"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.573"},{"key":"e_1_3_4_28_1","first-page":"110","article-title":"Efficacy, safety and cost analysis of SC vs IV rituximab in patients with diffuse large B-cell lymphoma treated with RCHOP","volume":"3","author":"Di Rocco A","year":"2017","unstructured":"Di Rocco A , ScerboG, AnsuinelliMet al. Efficacy, safety and cost analysis of SC vs IV rituximab in patients with diffuse large B-cell lymphoma treated with RCHOP. Haematologica3, 110\u2013111 (2017).","journal-title":"Haematologica"},{"issue":"4","key":"e_1_3_4_29_1","article-title":"Rates of ipsilateral breast tumor recurrence (IBTR) following breast conserving surgery (BCS) and hypofractionated radiotherapy for ductal carcinoma in situ (DCIS)","volume":"77","author":"Dumitru D","year":"2017","unstructured":"Dumitru D , BensonJ, WishartGet al. Rates of ipsilateral breast tumor recurrence (IBTR) following breast conserving surgery (BCS) and hypofractionated radiotherapy for ductal carcinoma in situ (DCIS). Cancer Res.77(4 Suppl. 1), P1-11-03 (2017).","journal-title":"Cancer Res."},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2015.01.002"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3147-y"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.09.167"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.07.122"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2017.05.004"},{"key":"e_1_3_4_35_1","volume-title":"ISPOR 22nd Annual International Meeting","author":"Gomes G","year":"2017","unstructured":"Gomes G , HoR, RufinoCet al. Budget impact analysis of rituximab IV versus SC from public Brazilian hospital. ISPOR 22nd Annual International Meeting. Boston, MA (2017)."},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.04.137"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.03.002"},{"issue":"1","key":"e_1_3_4_38_1","first-page":"68","article-title":"Positive benefits of changing from IV rituximab administration to SC administration: a single centre experience","volume":"176","author":"Irwin S","year":"2017","unstructured":"Irwin S , RowntreeC, CoshHet al. Positive benefits of changing from IV rituximab administration to SC administration: a single centre experience. Br. J. Hematol.176(Suppl. 1), 68\u201369 (2017).","journal-title":"Br. J. Hematol."},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.087"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu524"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1546172"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.4236\/abcr.2016.51001"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2017.01.026"},{"issue":"1","key":"e_1_3_4_44_1","first-page":"A57","article-title":"Switching from IV to SC formulation of trastuzumab: costs and safety","volume":"24","author":"Lopez MA","year":"2017","unstructured":"Lopez MA , SamanesMA, TenaIPet al. Switching from IV to SC formulation of trastuzumab: costs and safety. Eur. J. Hosp. Pharm.24(Suppl. 1), A57 (2017).","journal-title":"Eur. J. Hosp. Pharm."},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-017-1684-4"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.173583"},{"issue":"4","key":"e_1_3_4_47_1","article-title":"Comparative analysis of costs between SC formulation of trastuzumab versus IV formulation from the perspective of the Instituto Oncol\u00f3gico Nacional of Panam\u00e1 from January to December 2016","volume":"78","author":"Martin C","year":"2018","unstructured":"Martin C , AlcedoJ, Ara\u00fazE. Comparative analysis of costs between SC formulation of trastuzumab versus IV formulation from the perspective of the Instituto Oncol\u00f3gico Nacional of Panam\u00e1 from January to December 2016. Cancer Res.78(Suppl.4), P4-12-13 (2018).","journal-title":"Cancer Res."},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(18)30544-6"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.124347"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.05.342"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123866"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.08.143"},{"key":"e_1_3_4_53_1","first-page":"A216","article-title":"SC trastuzumab versus IV trastuzumab: an impact study","volume":"24","author":"Nierenberger A","year":"2017","unstructured":"Nierenberger A , GessierF, ForgesFet al. SC trastuzumab versus IV trastuzumab: an impact study. Eur. J. Hosp. Pharm.24, A216 (2017).","journal-title":"Eur. J. Hosp. Pharm."},{"issue":"2","key":"e_1_3_4_54_1","first-page":"600","article-title":"Cost-minimization analysis of rituximab SC formulation versus IV administration of rituximab for the treatment of non-Hodgkin\u2019s lymphoma in the Republic of Macedonia","volume":"102","author":"Nikolov O","year":"2017","unstructured":"Nikolov O , SterjevZ, DimovskiAet al. Cost-minimization analysis of rituximab SC formulation versus IV administration of rituximab for the treatment of non-Hodgkin\u2019s lymphoma in the Republic of Macedonia. Haematologica102(Suppl. 2), 600 (2017).","journal-title":"Haematologica"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S85599"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2016.07.008"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2017-0048"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.07.092"},{"key":"e_1_3_4_59_1","first-page":"5217","article-title":"SC compared to IV administration of rituximab plus CHOP in patients with diffuse large B-cell lymphoma \u2013 a study by the Polish Lymphoma Research Group","volume":"130","author":"Paszkiewicz-Kozik E","year":"2017","unstructured":"Paszkiewicz-Kozik E , Dlugosz-DaneckaM, RobakPJet al. SC compared to IV administration of rituximab plus CHOP in patients with diffuse large B-cell lymphoma \u2013 a study by the Polish Lymphoma Research Group. Blood130, 5217 (2017).","journal-title":"Blood"},{"issue":"4","key":"e_1_3_4_60_1","article-title":"Preference of trastuzumab administration route (IV or SC) in patients in the Czech Republic. Cross-sectional study on 429 patients","volume":"77","author":"Petrakova K","year":"2017","unstructured":"Petrakova K , MelicharB, BortlicekZet al. Preference of trastuzumab administration route (IV or SC) in patients in the Czech Republic. Cross-sectional study on 429 patients. Cancer Res.77(Suppl.4), P4-21-12 (2017).","journal-title":"Cancer Res."},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70383-8"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu364"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.05.009"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e18848"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S97319"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S97323"},{"key":"e_1_3_4_67_1","doi-asserted-by":"crossref","unstructured":"Poquet-Jornet JE CarreraHueso J CrespoCet al. Budget impact analysis with use of subcutaneus trastuzumab. ISPOR Europe Barcelona Spain (2018) PCN80.","DOI":"10.1016\/j.jval.2018.09.162"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.08.152"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.914033"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw685"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172996"},{"key":"e_1_3_4_72_1","first-page":"S32","article-title":"Preference of Macedonian NHL patients for SC vs IV administration of rituximab","volume":"61","author":"Stojanovik A","year":"2017","unstructured":"Stojanovik A , CvetanovskaL, ChevreskaLet al. Preference of Macedonian NHL patients for SC vs IV administration of rituximab. Leukemia Res.61, S32 (2017).","journal-title":"Leukemia Res."},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS16-P4-21-15"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2017.12.006"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.08.255"},{"key":"e_1_3_4_76_1","first-page":"298","article-title":"Management, economic and social impact of sub-cutaneous rituximab administration in lymphoproliferative malignancies","volume":"102","author":"Tomarchio V","year":"2017","unstructured":"Tomarchio V , SuranoMA, TafuriMAet al. Management, economic and social impact of sub-cutaneous rituximab administration in lymphoproliferative malignancies. Haematologica102, 298 (2017).","journal-title":"Haematologica"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/927105"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.03.006"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.025734"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00381-2"},{"issue":"1","key":"e_1_3_4_81_1","first-page":"4676","article-title":"Home administration of subcutaneous rituximab is safe and associated with significant cost saving: a single center experience","volume":"130","author":"Wolfromm A","year":"2017","unstructured":"Wolfromm A , MittaineB, GandrilleNet al. Home administration of subcutaneous rituximab is safe and associated with significant cost saving: a single center experience. Blood130(Suppl. 1), 4676 (2017).","journal-title":"Blood"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0339"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0610-z"},{"issue":"5","key":"e_1_3_4_85_1","first-page":"319","article-title":"Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab","volume":"32","author":"Pimentel F","year":"2018","unstructured":"Pimentel F , MorganG, TiezziDGet al. Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab. Pharmaceut. Med.32(5), 319\u2013325 (2018).","journal-title":"Pharmaceut. Med."},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-1954-6"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0316-z"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.035"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2019.02.008"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2019-0368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:34Z","timestamp":1719125134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2019-0368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,9]]},"references-count":87,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2019,10,31]]}},"alternative-id":["10.2217\/fon-2019-0368"],"URL":"https:\/\/doi.org\/10.2217\/fon-2019-0368","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-06-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}